We use cookies to help provide and enhance our service and tailor content and advertisements. Disable them / read more. By continuing or closing this message you agree to the use of cookies.
AbbVie, Allergan well-positioned for unconditional clearance in Brazil
22 Oct 2019 12:41 pm by Ana Paula Candil
AbbVie’s $63 million merger with Allergan is well-positioned for unconditional antitrust clearance in Brazil, MLex has learned.
Approval by the Administrative Council for Economic Defense, or CADE, is expected to be announced soon.
AbbVie and Allergan submitted merger paperwork on Aug. 22, but amended their notification form, pushing the review deadline to Nov. 14.
AbbVie and Allergan are listed on the New York Stock Exchange.
Related Articles
-
Google had a “state of play” meeting with EU merger case handlers yesterday to discuss its planned acquisition of fitness tracker company Fitbit. -
Facebook's purchase of the animated image company Giphy is sparking feedback to the US Federal Trade Commission, MLex has learned. -
Facebook’s track record of strategic acquisitions lie at the heart of the Australian regulator’s decision to probe the platform’s decision to acquire Giphy.